Pemetrexed disodium
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2004
- First approval year
- 2004
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Pemetrexed disodium
- Molecular weight
- 471.38
- Structure (SMILES)
- Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])cc3)c2c(=O)[nH]1.[Na+].[Na+]
- alimta
- Alimta
- pemetrexed baxter
- Pemetrexed baxter
- pemetrexed lilly
- Pemetrexed lilly
- pemetrexed sandoz
- Pemetrexed sandoz
- disodium n p 2 2 amino 4 7 dihydro 4 oxo 1h pyrrolo 2 3 d pyrimidin 5 yl ethyl benzoyl l glutamate
- DISODIUM N-(P-(2-((2-AMINO-4,7-DIHYDRO-4-OXO-1H-PYRROLO(2,3-D)PYRIMIDIN-5-YL)ETHYL)BENZOYL)-L-GLUTAMATE
- l glutamic acid n 4 2 2 amino 4 7 dihydro 4 oxo 1h pyrrolo 2 3 d pyrimidin 5 yl ethyl benzoyl disodium salt
- L-GLUTAMIC ACID, N-(4-(2-(2-AMINO-4,7-DIHYDRO-4-OXO-1H-PYRROLO(2,3-D)PYRIMIDIN-5-YL)ETHYL)BENZOYL)-, DISODIUM SALT
- ly 231514 disodium salt
- LY-231514 DISODIUM SALT
- ly231514 disodium salt
- LY231514 DISODIUM SALT
- pemetrexed baxter 500 mg powder for concentrate for solution for infusion
- pemetrexed disodium
- Pemetrexed disodium
- Pemetrexed Disodium
- PEMETREXED DISODIUM [ORANGE BOOK]
- PEMETREXED DISODIUM [USAN]
- PEMETREXED DISODIUM [USP MONOGRAPH]
- PEMETREXED DISODIUM [USP-RS]
- Pemetrexed disodium [WHO-DD]
- Pemetrexed disodium for injection
- Pemetrexed Disodium for Injection
- pemetrexed disodium heptahydrate
- Pemetrexed disodium heptahydrate
- Pemetrexed Disodium Heptahydrate
- Pemetrexed Disodium Injection
- pemetrexed disodium orange book
- pemetrexed disodium usan
And 9 more, listed on the interactive page.
- CAS registry numbers
- 150399-23-8
- ChEMBL ID
- CHEMBL2360464
- InChIKey
- NYDXNILOWQXUOF-GXKRWWSZSA-L
- RxNorm IDs (RxCUI)
- 282443
- FDA ingredient codes (UNII)
- 2PKU919BA9
- 101068009
- 135413520
- 136068113
- Applicant
- SANDOZ
- Approval date
- 26 May 2022
- Application number
- NDA214657
- Patents
- 1
- Designations
- 3
- Earliest recorded loss of exclusivity
- 26 Mar 2035
- First in class
- No
- Fast track
- Yes
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Drug name stem
- -trexed
Administration routes
- Parenteral
- Mechanism
- Dihydrofolate reductase inhibitor
- Action type
- Inhibitor
- Target
- Dihydrofolate reductase
- Protein identifier
- P00374
- Mechanism
- GAR transformylase inhibitor
- Action type
- Inhibitor
- Target
- Trifunctional purine biosynthetic protein adenosine-3
- Protein identifier
- P22102
- Mechanism
- Thymidylate synthase inhibitor
- Action type
- Inhibitor
- Target
- Thymidylate synthase
- Protein identifier
- P04818
- Mechanism
- Dihydrofolate reductase inhibitor
- Action type
- Inhibitor
- Target
- Dihydrofolate reductase
- Mechanism
- GAR transformylase inhibitor
- Action type
- Inhibitor
- Target
- Trifunctional purine biosynthetic protein adenosine-3
- Mechanism
- Thymidylate synthase inhibitor
- Action type
- Inhibitor
- Target
- Thymidylate synthase
- Condition
- Adenocarcinoma, Bronchiolo-Alveolar
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000308
- Subject identifier
- D002282
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000365
- Subject identifier
- D015179
- Condition
- Adenocarcinoma of Lung
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000571
- Subject identifier
- D000077192
- Condition
- Lymphoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Mesothelioma
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000588
- Subject identifier
- D008654
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Sarcoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000691
- Subject identifier
- D012509
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000708
- Subject identifier
- D002294
- Condition
- Mesothelioma
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000770
- Subject identifier
- D008654
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition
- Carcinoma, Large Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003050
- Subject identifier
- D018287
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003860
- Subject identifier
- D010190
- Condition
- Urogenital Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003863
- Subject identifier
- D014565
- Condition
- Head and Neck Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0006859
- Subject identifier
- D006258
- Condition
- Urinary Bladder Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0008528
- Subject identifier
- D001749
- Condition
- Neoplasm Metastasis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0009708
- Subject identifier
- D009362
- Condition
- Mesothelioma, Malignant
- Highest recorded phase
- 4
- Condition identifier
- EFO:1000355
- Subject identifier
- D000086002
- Condition
- Thymoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000576
- Subject identifier
- D013945
- Condition
- Thymoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000581
- Subject identifier
- D013945
- Condition
- Salivary Gland Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0000521
- Subject identifier
- D012468
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0001056
- Subject identifier
- D013274
- Condition
- Urinary Bladder Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0001187
- Subject identifier
- D001749
- Condition
- Peritoneal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002087
- Subject identifier
- D010534
- Condition
- Fallopian Tube Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0002158
- Subject identifier
- D005185
And 14 more, listed on the interactive page.
- Condition identifier
- EFO_0000365
- Condition identifier
- EFO_0000588
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000691
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002618
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003060
- Condition identifier
- EFO_0006859
- Highest recorded phase
- 2
- Condition identifier
- EFO_0008528
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000576
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000581
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001012
- Highest recorded phase
- 1
- Condition identifier
- EFO_1001941
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002087
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002158
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002447
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002571
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002974
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0003220
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0003308
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004669
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004986
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005061
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005062
- Highest recorded phase
- 1
And 28 more, listed on the interactive page.
- Event
- acute kidney injury
- Reports
- 353
- Reporting signal score
- 211.145
- Event
- anaemia
- Reports
- 679
- Reporting signal score
- 570.386
- Event
- bone marrow failure
- Reports
- 143
- Reporting signal score
- 168.748
- Event
- colitis
- Reports
- 125
- Reporting signal score
- 112.486
- Event
- decreased appetite
- Reports
- 284
- Reporting signal score
- 126.385
- Event
- dehydration
- Reports
- 252
- Reporting signal score
- 125.46
- Event
- disease progression
- Reports
- 345
- Reporting signal score
- 327.897
- Event
- febrile neutropenia
- Reports
- 318
- Reporting signal score
- 342.381
- Event
- general physical health deterioration
- Reports
- 241
- Reporting signal score
- 206.677
- Event
- injection site pain
- Reports
- 2
- Reporting signal score
- 110.901
- Event
- interstitial lung disease
- Reports
- 208
- Reporting signal score
- 207.554
- Event
- leukopenia
- Reports
- 208
- Reporting signal score
- 173.429
- Event
- lung adenocarcinoma
- Reports
- 56
- Reporting signal score
- 132.067
- Event
- malignant neoplasm progression
- Reports
- 516
- Reporting signal score
- 852.899
- Event
- mucosal inflammation
- Reports
- 165
- Reporting signal score
- 197.14
- Event
- myelosuppression
- Reports
- 103
- Reporting signal score
- 164.802
- Event
- neutropenia
- Reports
- 502
- Reporting signal score
- 412.535
- Event
- neutrophil count decreased
- Reports
- 173
- Reporting signal score
- 169.862
- Event
- non-small cell lung cancer
- Reports
- 89
- Reporting signal score
- 269.279
- Event
- pancytopenia
- Reports
- 410
- Reporting signal score
- 600.909
- Event
- pleural effusion
- Reports
- 172
- Reporting signal score
- 123.011
- Event
- pneumonitis
- Reports
- 143
- Reporting signal score
- 176.761
- Event
- therapy partial responder
- Reports
- 75
- Reporting signal score
- 140.711
- Event
- thrombocytopenia
- Reports
- 502
- Reporting signal score
- 457.892
- Event
- tubulointerstitial nephritis
- Reports
- 118
- Reporting signal score
- 161.63
And 1 more, listed on the interactive page.
- NCT00003706
- NCT00003711
- NCT00070473
- NCT00320073
- NCT00390000
- NCT00573690
- NCT01450384
- NCT06116240
- NCT00005636
- NCT00101283
- NCT00227630
- NCT00541073
- NCT01085630
- NCT01105390
- NCT00006007
- NCT00097383
- NCT00022646
- NCT00117962
- NCT00227539
- NCT00227565
- NCT00248495
- NCT00268489
- NCT00280748
- NCT00301808
- NCT00387322
And 78 more, listed on the interactive page.
- Dose
- 500 mg/m2
- Route
- Intravenous
- How often
- Every 3 weeks
Conditions of use
- Administer over 10 minutes
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 6
- Polar surface area
- 191.26
- Calculated partition coefficient (ALogP)
- 0.67
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 9
- Heavy atoms
- 33
- Molecular formula
- C20H19N5Na2O6
- Monoisotopic mass
- 471.11307191
- Natural product
- Yes
- 0409-0004
- 0409-0020
- 0409-0021
- 0409-1045
- 0409-2188
- 0409-3532
- 0781-3518
- 0781-3519
- 0781-3520
- 43598-370
- 43598-386
- 43598-387
- 63323-134
- 63323-450
- 63323-621
- 63323-622
- 68001-543
- 68001-544
- 68001-545
- 68001-546
- 70710-1654
- 70710-1655
- 70710-1674
- 70771-1691
- 70771-1692
And 1 more, listed on the interactive page.
- Recorded assays
- 144
- Active assays
- 12
Active assay types
- Confirmatory
Related records
Trials (101)
- A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
- A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors
- A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer
- A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
- A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma
- A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
- A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
- A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
- A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer
- A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer
- A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
- A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).
- Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
- AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma
- Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
- Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
- AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer
- Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
- Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
- Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)
Approved for (4)
- Malignant mesothelioma
- Malignant pleural mesothelioma
- Mesothelioma
- Non-small cell lung carcinoma
In development for (33)
- Breast cancer Phase 2
- Cancer Phase 1
- Cervical cancer Phase 2
- Colorectal adenocarcinoma Phase 2
- Colorectal cancer Phase 2
- Endometrial cancer Phase 2
- Exocrine pancreatic carcinoma Phase 3
- Fallopian tube cancer Phase 1
- Gallbladder cancer Phase 1
- Gastric cancer Phase 2
- Gestational trophoblastic neoplasm Phase 2
- Head and neck cancer Phase 2
- Liver cancer Phase 1
- Lung adenocarcinoma Phase 2
- Lung cancer Phase 3
- Lung large cell carcinoma Phase 2
- Lung neoplasm Phase 3
- Lymphoma Phase 1
- Minimally invasive lung adenocarcinoma Phase 2
- Neoplasm Phase 1